Introduction: Sepsis is a common cause of morbidity and mortality in the neonatal intensive care unit (NICU). The frequency and severity of sepsis-associated coagulopathy as well as its relationship to illness severity are unclear.

Methods: We performed a single-center, retrospective, observational cohort study of all infants admitted to the University of Florida Health (UF Health), level IV NICU between January 1st 2012 to March 1st 2020 to measure the frequency of sepsis-associated coagulopathy as well as its temporal relationship to critical illness in the NICU population. All clinical data in the electronic health record were extracted and deposited into an integrated data repository that was used for this work.

Results: We identified 225 new sepsis episodes in 216 patients. An evaluation for sepsis-associated coagulopathy was performed in 96 (43%) episodes. Gram-negative pathogen, nSOFA score at evaluation, and mortality were greater among episodes that included a coagulopathy evaluation compared with those that did not. Abnormal coagulation results were common (271/339 evaluations; 80%) and were predominantly prothrombin times. Intervention (plasma or cryoprecipitate) followed a minority (84/271; 31%) of abnormal results, occurred in 40/96 (42%) episodes that were often associated with >1 intervention (29/40; 73%), and coincided with thrombocytopenia in 37/40 (93%) and platelet transfusion in 27/40 (68%). Shapley Additive Explanations modeling demonstrated strong predictive performance for the composite outcome of death and/or treatment for coagulopathy in neonates (f1 score 0.8, area under receiver operating characteristic curve 0.83 for those with abnormal coagulation values). The three most important features influencing the composite outcome of death or treatment for coagulopathy included administration of vasoactive medications, hematologic dysfunction assessed by the maximum nSOFA platelet score, and early sepsis (≤72 h after birth).

Conclusions: A coagulopathy evaluation was performed in a minority of NICU patients with sepsis and was associated with greater illness severity and mortality. Abnormal results were common but infrequently associated with intervention, and intervention was contemporaneous with thrombocytopenia. The most important feature that influenced the composite outcome of death or treatment for coagulopathy was the administration of vasoactive-inotropic medications. These data help to identify NICU patients at risk of sepsis-associated coagulopathy.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10948397PMC
http://dx.doi.org/10.3389/fped.2024.1364725DOI Listing

Publication Analysis

Top Keywords

sepsis-associated coagulopathy
20
composite outcome
12
outcome death
12
treatment coagulopathy
12
coagulopathy
10
neonatal intensive
8
intensive care
8
care unit
8
coagulopathy well
8
illness severity
8

Similar Publications

Background: Sepsis-induced disseminated intravascular coagulopathy (DIC) remains a challenging clinical entity associated with significant morbidity and mortality. Endothelial injury or activation and extracellular vesicles (EV) are postulated as important determinants of DIC.

Objectives: The aim of this study was to test the discriminatory ability of E-selectin, EV, tissue factor (TF) and TF pathway inhibitor (TFPI) in sepsis-induced coagulopathy.

View Article and Find Full Text PDF
Article Synopsis
  • Sepsis is a severe condition marked by inflammation and blood vessel dysfunction, leading to high hospital mortality rates, and new methods are needed to combat it.
  • Research has shown that using drag-reducing polymers (DRPs) can enhance blood flow and oxygen delivery in the body, providing protection to brain cells in traumatic situations.
  • In experiments with mice, DRPs improved microcirculation and oxygen supply, reducing harmful effects of sepsis compared to a control group that only received saline, indicating their potential as a treatment strategy for sepsis-related complications.
View Article and Find Full Text PDF
Article Synopsis
  • Sepsis, affecting 49 million people annually, poses serious management challenges, particularly concerning coagulopathy, and while heparin may offer benefits, there’s no strong evidence supporting its use in sepsis cases.
  • A systematic review following PRISMA guidelines was conducted, analyzing randomized control trials involving heparin in adult sepsis patients, with primary focus on 28-day mortality and bleeding complications.
  • The meta-analysis, which included three qualifying studies with 426 patients, found no significant mortality benefits from heparin, but indicated lower bleeding complications, suggesting more research is needed to explore heparin’s role in sepsis treatment.
View Article and Find Full Text PDF

Objective: The objective of this study was to investigate the differential expression of genes associated with coagulation in bovine monocyte-derived macrophages (MoMΦ) exposed to lipopolysaccharide (LPS) in vitro. We hypothesized that MoMΦ stimulated with LPS would have upregulation of procoagulant genes and downregulation of genes protecting against coagulation.

Methods: MoMΦ were isolated from Holstein steers and exposed to Escherichia coli-derived LPS or a control for 3 hours.

View Article and Find Full Text PDF

Sepsis-associated coagulopathy increases risk of mortality. Impairment of the anticoagulant protein C (PC) pathway may contribute to the thrombotic phenotype in coronavirus disease 2019 (COVID-19) sepsis. This study assessed the functionality of this pathway in COVID-19 and non-COVID sepsis by measuring its key enzymes, thrombin and activated PC (APC).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!